Figure 5.
Enitociclib is effective against MM in vivo. (A-B) In vivo mechanism of action of enitociclib in mice bearing JJN-3 MM xenografts upon a single dose of 15 mg/kg enitociclib administered IV compared with 80% PEG400 vehicle. Messenger RNA transcript (A) and protein levels (B) were normalized to housekeeping genes in L32 and β-actin, respectively. (C) In vivo antitumor activity of enitociclib administered as a single agent. For JJN-3, NCI-H929, and OPM-2 MM xenografts, enitociclib was dosed 15 mg/kg IV once weekly compared with vehicle control. (D) To study combinations, enitociclib was dosed 15 mg/kg IV once weekly in combination with 50 mg/kg lenalidomide orally daily or 0.8 mg/kg bortezomib intraperitoneally twice weekly in OPM-2 MM xenografts. ∗P < .05.

Enitociclib is effective against MM in vivo. (A-B) In vivo mechanism of action of enitociclib in mice bearing JJN-3 MM xenografts upon a single dose of 15 mg/kg enitociclib administered IV compared with 80% PEG400 vehicle. Messenger RNA transcript (A) and protein levels (B) were normalized to housekeeping genes in L32 and β-actin, respectively. (C) In vivo antitumor activity of enitociclib administered as a single agent. For JJN-3, NCI-H929, and OPM-2 MM xenografts, enitociclib was dosed 15 mg/kg IV once weekly compared with vehicle control. (D) To study combinations, enitociclib was dosed 15 mg/kg IV once weekly in combination with 50 mg/kg lenalidomide orally daily or 0.8 mg/kg bortezomib intraperitoneally twice weekly in OPM-2 MM xenografts. ∗P < .05.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal